Healthcare Providers and Services
Company Overview of Fox Chase Cancer Center
Fox Chase Cancer Center owns and operates a cancer care hospital in Philadelphia. It offers surgery, radiation oncology, virtual colonoscopy, diagnostic imaging, and breast imaging center of excellence seal services; and develops various therapies and technologies for treating cancer. The company also provides breast evaluation, risk assessment, and cancer education services; and conducts basic, translational, and clinical research with special programs in cancer prevention, detection, survivorship, and community outreach. In addition, it offers fellowship training in breast cancer, hematology, pathology, surgical oncology, advanced minimally invasive thoracic surgery, and urologic oncology....
333 Cottman Avenue
Philadelphia, PA 19111-2497
Founded in 1904
Key Executives for Fox Chase Cancer Center
Chief Executive Officer, President and Cancer Center Director
President of Friends of The Hospital
President of Fox Chase Chapter
Compensation as of Fiscal Year 2015.
Fox Chase Cancer Center Key Developments
Horizon Pharma plc Announces Collaboration with Fox Chase Cancer Center to Study ACTIMMUNE (interferon Gamma 1b) in Combination with PD-1/PD-L1 Inhibitors in Various Forms of Cancer
Jul 27 15
Horizon Pharma plc announced a collaboration with Fox Chase Cancer Center to study ACTIMMUNE (interferon gamma-1b) in combination with PD-1/PD-L1 inhibitors in various forms of cancer including advanced urothelial carcinoma (bladder cancer) and renal cell carcinoma. Preclinical cell line research has indicated that interferon gamma enhances cellular PD-L1 expression on endothelial cells (inner lining of the blood vessel) and on some tumor cells. By enhancing cellular PD-L1 expression on tumor cells, interferon gamma may promote or enhance the effect of the PD-1 or PD-L1 inhibitors. The first study being planned as part of the collaboration will be a dose-ranging study to determine a suitable dose for ACTIMMUNE with PD-1/PD-L1 inhibition. Once the ideal combination strategy is determined, the investigators intend to expand the study to include patients with metastatic bladder and renal cell carcinomas. Additional studies are expected to follow depending on initial results.
Oncoceutics and Fox Chase Cancer Center Announce an Agreement to Conduct Clinical Testing with ONC201
Jul 13 15
Oncoceutics and Fox Chase Cancer Center have announced an agreement to conduct clinical testing with ONC201, a novel first-in-class small molecule compound being developed by the company. The study led by Dr. Anthony Olszanski, director of the Phase I Experimental Therapeutics Program at Fox Chase Cancer Center, will systematically assess dose escalation with three different schedules for oral ONC201 ranging from every three week to one week administration. ONC201 showed a benign safety profile, as well as early signs of activity, at therapeutic doses in the first Phase I study conducted at the Cancer Institute of New Jersey. The clinical trial at Fox Chase Cancer Center makes use of the excellent tolerability of ONC201 and recent preclinical data generated at Fox Chase Cancer Center that suggests single agent ONC201 has profound antitumor activity that, in certain circumstances, can be further optimized when given more frequently. The strong tumor-depleting activity as a single agent is a feature that is facilitated by its ability to eliminate cancer stem cells and spare normal cells. The clinical study is part of a larger academic/corporate partnership between Fox Chase Cancer Center and Oncoceutics. This close relationship is rooted in a long history of Dr. Wafik El-Deiry's research on cell death pathways that allow cancer cells to escape the lethal effects of anti-cancer drugs. ONC201 emerged from laboratory research in his group as a first-in-class oral compound that is effective in a broad spectrum of tumor types that are being evaluated in the clinic. Dr. El-Deiry is a Professor of Medical Oncology, Deputy Director for Translational Research and co-Leader of the Molecular Therapeutics Program at Fox Chase Cancer Center. He is also an American Cancer Society Research Professor and the Scientific Founder of Oncoceutics.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries